Salient Pharma ApS: Financial statements 2016
CVR: 36900709
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
Salient Pharma ApS (CVR 36900709) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK -954,993 and a net result of DKK -772,477. Equity in the 2016 report amounted to DKK -847,215.
- Gross Profit
- DKK -954,993
- Profit/Loss
- DKK -772,477
- Equity
- DKK -847,215
- Total Assets
- DKK 592,309
Official annual report
Find more companies like Salient Pharma ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2016
Salient Pharma ApS has published its interim report for the period May 21, 2015 – December 31, 2015.
About Salient Pharma ApS
Salient Pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Ulrik Spork. The board consists of Helle Bøwadt, Søren Wang Petersen and Ulrik Spork. The company is owned by HB-MEDICAL HOLDING ApS, CAND.PHARM. POVL M. ASSENS FOND and SPORCON LIFESCIENCE ADVISORS ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -129,889 and a net result of DKK -218,345 compared with DKK -202,180 the year before. Equity in the 2025 report amounted to DKK -1,344,010.